Alphatec (NASDAQ:ATEC) Stock Price Crosses Below 200-Day Moving Average After Earnings Miss

Alphatec Holdings, Inc. (NASDAQ:ATEC)’s share price passed below its 200-day moving average during trading on Friday after the company announced weaker than expected quarterly earnings. The stock has a 200-day moving average of $10.62 and traded as low as $6.81. Alphatec shares last traded at $7.04, with a volume of 27,294,109 shares traded.

The medical technology company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). The business had revenue of $221.17 million during the quarter, compared to analysts’ expectations of $225.16 million. Alphatec had a negative return on equity of 6,752.24% and a negative net margin of 10.35%. The company’s quarterly revenue was up 12.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.03 EPS.

Key Stories Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Third-quarter revenue increased 12.6% year over year to approximately $221.2 million, while earnings of $0.09 per share improved from $0.03 a year earlier. Management continues to target a 16% adjusted EBITDA margin for 2026. Alphatec third-quarter results
• Positive Sentiment: Wells Fargo lowered its price target from $14 to $12 but maintained an “overweight” rating, implying substantial potential upside if Alphatec stabilizes growth and executes on its profitability plans. Wells Fargo rating
• Neutral Sentiment: Analyst expectations remain divided: BMO Capital Markets downgraded the stock to “market perform” with an $8 price target, while other analysts continue to see valuation upside. BMO Capital Markets rating
• Negative Sentiment: Alphatec reduced its 2026 revenue outlook to approximately $862 million from roughly $882 million, below the prior market expectation. Management cited fewer surgeons purchasing its bone-graft products used in spinal-fusion procedures. Alphatec guidance reduction
• Negative Sentiment: Third-quarter adjusted earnings of $0.09 per share and revenue of $221.2 million both missed analyst estimates, reinforcing concerns about slowing demand despite year-over-year growth. Alphatec earnings miss
• Negative Sentiment: Levi & Korsinsky and Ademi LLP announced investigations into potential securities-law violations related to Alphatec’s outlook and subsequent decline. These notices may add reputational and legal risk, although they do not establish wrongdoing. Alphatec investor investigation

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ATEC. Stifel Nicolaus dropped their target price on shares of Alphatec from $16.00 to $13.00 and set a “buy” rating for the company in a research report on Wednesday, July 8th. TD Cowen decreased their price target on shares of Alphatec from $13.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday. Wells Fargo & Company dropped their price objective on shares of Alphatec from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday. JPMorgan Chase & Co. cut their price objective on Alphatec from $16.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday. Finally, UBS Group raised their price objective on Alphatec from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

Insider Buying and Selling

In other Alphatec news, CEO Patrick Miles purchased 115,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were bought at an average price of $8.81 per share, with a total value of $1,013,150.00. Following the completion of the purchase, the chief executive officer directly owned 5,893,551 shares in the company, valued at $51,922,184.31. This trade represents a 1.99% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Tyson Marshall sold 8,168 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the transaction, the general counsel owned 630,398 shares of the company’s stock, valued at $6,083,340.70. This trade represents a 1.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Alphatec

Hedge funds have recently made changes to their positions in the business. State of Wyoming lifted its holdings in shares of Alphatec by 87.7% in the 3rd quarter. State of Wyoming now owns 30,666 shares of the medical technology company’s stock valued at $316,000 after acquiring an additional 14,328 shares during the last quarter. Sterling Capital Management LLC grew its position in Alphatec by 841.5% in the third quarter. Sterling Capital Management LLC now owns 4,105 shares of the medical technology company’s stock worth $42,000 after acquiring an additional 3,669 shares in the last quarter. Kopp Family Office LLC increased its stake in Alphatec by 0.4% during the third quarter. Kopp Family Office LLC now owns 330,266 shares of the medical technology company’s stock worth $3,408,000 after acquiring an additional 1,303 shares during the last quarter. AA Financial Advisors LLC increased its stake in Alphatec by 140.5% during the third quarter. AA Financial Advisors LLC now owns 48,094 shares of the medical technology company’s stock worth $496,000 after acquiring an additional 28,094 shares during the last quarter. Finally, Congress Asset Management Co. increased its stake in Alphatec by 20.7% during the third quarter. Congress Asset Management Co. now owns 532,069 shares of the medical technology company’s stock worth $5,491,000 after acquiring an additional 91,431 shares during the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Price Performance

The business has a 50-day simple moving average of $10.14 and a 200-day simple moving average of $10.62. The firm has a market capitalization of $1.09 billion, a PE ratio of -12.80 and a beta of 0.78.

Alphatec Company Profile

Alphatec Holdings, Inc is a medical technology company focused on the design, development and commercialization of products and procedural solutions for spine surgery. The company aims to improve the treatment of spinal disorders through technologies that support spinal fusion, deformity correction, reconstruction and minimally invasive procedures.

Its portfolio includes spinal implants, surgical instruments, navigation and imaging technologies, and intraoperative monitoring solutions.